FDA Oncology Announcements

TRK inhibitor × Clear all

3 Announcements

FDA expands pediatric indication for entrectinib and approves new pellet formulation

Trial: STARTRK-NG
Drug: Rozlytrek (entrectinib) · TRK inhibitor
Condition: Other solid neoplasm

FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC

Trials: STARTRK-1, STARTRK-2
Drug: ROZLYTREK (entrectinib) · TRK inhibitor
Conditions: Other solid neoplasmThoracic

FDA approves larotrectinib for solid tumors with NTRK gene fusions

Drug: VITRAKVI (larotrectinib) · TRK inhibitor
Condition: Other solid neoplasm